Blue Owl is highlighted as a deep value investment opportunity with improving fundamentals and a strong recovery from previous market pessimism. Its real assets segment has driven 44% revenue growth over the past year, with expectations for continued strong performance. The company is nearing full dividend coverage, with management forecasting to exceed consensus estimates and fully cover dividends by year-end. At an 18x price-to-distributable-earnings ratio, Blue Owl projects a total return of 69% through 2027, offering investors nearly an 8% yield and solid dividend growth potential for the long term.
Ethereum's upcoming Glamsterdam upgrade introduces a new gas fee structure that breaks the long-standing 21,000 gas rule for ETH transfers. While transfers to existing accounts still cost 21,000 gas, creating a new account now incurs additional state...
Micron Technology reported a fiscal Q3 revenue surge to $41.456 billion, driven by rapid HBM4 memory sales, while SK Hynix posted a record Q2 2026 revenue of 79.3 trillion won, fueled by HBM sales. Micron's contracts lock in significant revenue and m...
David Schwartz, Ripple's former CTO, revealed that his XRP holdings have dropped significantly from about 26 million at their peak to roughly 2 million XRP now, a decline of around 92%. While he did not specify how he reduced his holdings, possibilit...
Ethereum's upcoming Glamsterdam upgrade changes the long-standing rule that every basic ETH transfer costs a flat 21,000 gas units. Transfers to existing accounts will still cost 21,000 gas, but sending ETH to a new, never-before-used address will re...
ARS Pharmaceuticals has seen its stock fall more than 65% due to significant commercialization difficulties. The company's new CEO plans to revitalize its FDA-approved no-needle epinephrine product, Neffy, through strict cost controls and focused phy...
